InMed Pharmaceuticals Inc. (NASDAQ: INM) has unveiled promising preclinical data for its drug candidate INM-901, demonstrating significant reductions in neuroinflammation, a key factor in Alzheimer's disease progression. The findings, which show a dose-dependent decrease in pro-inflammatory cytokines and inflammasome markers, suggest INM-901's potential as a novel treatment approach, independent of traditional amyloid beta or tau pathology targets.
The orally administered compound, targeting CB1/CB2 receptors and PPARs, has also shown improvements in cognition and behavior in long-term animal studies. This positions INM-901 as a potential breakthrough in addressing the high unmet medical needs in neurodegenerative diseases, with Alzheimer's disease as the lead indication for further development.
InMed Pharmaceuticals plans to advance INM-901 through additional preclinical and IND-enabling studies, marking a significant step forward in the quest for effective Alzheimer's treatments. The full details of the preclinical results can be found in the company's press release at https://ibn.fm/HBoFJ.
